Kasparov A A, Solodovnik V D, Ermakov N V, Magden Iu
Vestn Oftalmol. 1998 May-Jun;114(3):10-2.
Endothelium protector SOFTEL is developed by Ekran firm and Institute of Eye Diseases, Russian Academy of Medical Sciences. The drug was used in 157 patients aged 28-79 years. Perforating keratoplasty for corneal leukoma and keratoconus was carried out in 46 patients, cataract extraction with implantation of intraocular lens (IOL) in 94, and cataract extraction without IOL implantation in 17 patients. Two patients developed slight hypertension in the postoperative period, which resolved within 24 h, and four patients developed moderate corneal edema persisting for 1-2 days postoperation. The protective effect of softel is compatible with that of its foreign analog Healon. The drug is effective in cataract extractions with IOL implantation and perforating keratoplasty.
内皮保护剂SOFTEL由叶克兰公司和俄罗斯医学科学院眼病研究所研制。该药物应用于157例年龄在28至79岁的患者。46例患者因角膜白斑和圆锥角膜接受了穿透性角膜移植术，94例患者接受了白内障摘除联合人工晶状体植入术，17例患者接受了白内障摘除但未植入人工晶状体。2例患者术后出现轻度高血压，在24小时内缓解，4例患者出现中度角膜水肿，术后持续1至2天。SOFTEL的保护作用与其国外同类产品Healon相当。该药物在白内障摘除联合人工晶状体植入术和穿透性角膜移植术中有效。
